As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.
Here are four biotechs to consider, two of which are involved in developing drugs to fight the Ebola virus.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Given the usual hype surrounding small-cap biotechs, Brainstorm CEO Tony Fiorino is refreshingly candid about the company's chances of developing a stem-cell treatment to counter ALS symptoms.
AbbVie's board is recommending stockholders vote against its $55 billion takeover offer for drugmaker Shire after tax changes reduced the financial advantages of the deal.
U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.
St. Jude Medical (STJ) shares are falling after the company forecast fourth quarter revenue below analyst expectations.
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
AbbVie (ABBV) shares are falling in pre-market trading after the company said that it is reconsidering it's $55 billion takeover bid for Shire Pharmaceuticals (SHPG).
Wall Street started the day rallying on track to break a three-day losing streak, but at the end lost steam and closed mixed on Tuesday.
TheStreet's Jim Cramer said he does not trust the market right now, given that quality stocks with good earnings results like J&J are moving lower.
It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.
On Tuesday, October 14th three major banks kick off a big week for third quarter earnings reports.
Health care investors can be divided into two camps with respect to Sarepta: Those who believe eteplirsen is effective against DMD and those who don't.
TheStreet's Jim Cramer says shares of Blackstone should move higher on its spinoff announcement, while shares of Exact Sciences fly higher on positive news for its alternative treatment to colonoscopies.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV